| Symbol | BIOA |
|---|---|
| Name | BIOAGE LABS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1445A SOUTH,50TH STREET, RICHMOND, California, 94804, United States |
| Telephone | 510-806-1445 |
| Fax | — |
| — | |
| Website | https://www.bioagelabs.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001709941 |
| Description | BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - BioAge Labs, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003686 <b>Size:</b> 9 KB
Read moreBioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
Read more📋 Barton Shane (Officer) plans to sell 42K shares of BioAge Labs, Inc. (at $25.21 each, total $1.1M) Filed: Jun 29, 2026 | ID: 004955
Read moreBioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Read morePande Vijay Satyanand 🟢 acquired 22.0K shares (1 derivative) of BioAge Labs, Inc. (BIOA) at $15.48 Transaction Date: Jun 10, 2026 | Filing ID: 000002
Read moreHemrajani Rekha 🟢 acquired 22.0K shares (1 derivative) of BioAge Labs, Inc. (BIOA) at $15.48 Transaction Date: Jun 10, 2026 | Filing ID: 000004
Read moreHEALY JAMES 🟢 acquired 22.0K shares (1 derivative) of BioAge Labs, Inc. (BIOA) at $15.48 Transaction Date: Jun 10, 2026 | Filing ID: 000002
Read moreENRIGHT PATRICK G 🟢 acquired 22.0K shares (1 derivative) of BioAge Labs, Inc. (BIOA) at $15.48 Transaction Date: Jun 10, 2026 | Filing ID: 000006
Read moreDavidson Michael H. 🟢 acquired 22.0K shares (1 derivative) of BioAge Labs, Inc. (BIOA) at $15.48 Transaction Date: Jun 10, 2026 | Filing ID: 000003
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07812090 | A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involve… | Phase2 | Diabetic Macular Edema (DME) | Recruiting | 2026-08-21 | 2027-12-01 | ClinicalTrials.gov |
| NCT07656727 | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BG… | Phase2 | Obesity and Cardiovascular Risk | Active_Not_Recruiting | 2026-06-11 | 2026-12-01 | ClinicalTrials.gov |
| NCT06515418 | Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared wit… | Phase2 | Obesity | Terminated | 2024-06-27 | 2025-02-12 | ClinicalTrials.gov |
| NCT06141889 | Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers | Phase1 | Healthy Volunteer Study | Completed | 2023-11-17 | 2024-02-02 | ClinicalTrials.gov |
| NCT04815603 | Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of … | Phase2 | Anemia | Withdrawn | 2021-03-22 | 2022-04-01 | ClinicalTrials.gov |
| NCT04705597 | Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospital… | Phase2 | Covid19 | Terminated | 2021-03-18 | 2022-05-19 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Sham | Other | Phase PHASE2 | Diabetic Macular Edema (DME) | RECRUITING | NCT07812090 |
| Anti-VEGF | Other | Phase PHASE2 | Diabetic Macular Edema (DME) | RECRUITING | NCT07812090 |
| Oral Placebo Matching BGE-102 | Other | Phase PHASE2 | Diabetic Macular Edema (DME) | RECRUITING | NCT07812090 |
| Oral BGE-102 | Other | Phase PHASE2 | Diabetic Macular Edema (DME) | RECRUITING | NCT07812090 |
| Oral Placebo Matching BGE-102 | Other | Phase PHASE2 | Obesity and Cardiovascular Risk | ACTIVE_NOT_RECRUITING | NCT07656727 |
| Oral BGE-102 | Other | Phase PHASE2 | Obesity and Cardiovascular Risk | ACTIVE_NOT_RECRUITING | NCT07656727 |
| Oral Placebo Matching BGE-102 | Other | Phase PHASE2 | Obesity and Cardiovascular Risk | RECRUITING | NCT07656727 |
| Oral BGE-102 | Other | Phase PHASE2 | Obesity and Cardiovascular Risk | RECRUITING | NCT07656727 |
| Placebo | Other | Phase PHASE2 | Anemia | WITHDRAWN | NCT04815603 |
| BGE-117 | Other | Phase PHASE2 | Anemia | WITHDRAWN | NCT04815603 |
| Placebo | Other | Phase PHASE2 | Covid19 | TERMINATED | NCT04705597 |
| BGE-175 | Other | Phase PHASE2 | Covid19 | TERMINATED | NCT04705597 |
| Azelaprag | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06141889 |
| Tirzepatide Placebo | Other | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Tirzepatide | Other | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Oral Placebo for Azelaprag (BGE-105) | Other | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Oral Azelaprag (BGE-105) | Other | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Tirzepatide Placebo | DRUG | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Tirzepatide | DRUG | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Oral Placebo for Azelaprag (BGE-105) | DRUG | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Oral Azelaprag (BGE-105) | DRUG | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |